BFH772 (VEGFR2 inhibitor): Lab Workflow Guide

BFH772 is a research compound for experiments that require targeted modulation of VEGFR2 kinase activity. The compound is described in the BFH772 (VEGFR2 inhibitor) product dossier as a potent VEGFR2 inhibitor with an IC₅₀ of 3 nM. Its reported selectivity profile makes it relevant to VEGFR2 signaling pathway inhibitor workflows, endothelial-cell angiogenesis assays, and tumor angiogenesis research compound screening.

No directly matched paper evidence was supplied for this article. Accordingly, product-specific numerical claims are limited to the dossier, while handling and assay recommendations are presented as workflow guidance that should be validated in the user’s own system.

What This Product Solves

Many angiogenesis experiments need a defined chemical perturbation rather than a broad kinase inhibitor. BFH772 addresses that use case by providing a small molecule with reported activity against VEGFR2 and reduced potency against the related receptor panel listed in the dossier. The product is therefore suited to experiments asking whether a VEGFR2-dependent response changes after selective kinase inhibition.

Potential applications include biochemical kinase assays, VEGFR2 pathway studies in responsive cells, endothelial migration or tube-formation experiments, and exploratory tumor-model work. These applications should be designed around measured exposure and vehicle controls rather than around the biochemical IC₅₀ alone. A biochemical potency value does not establish a cellular effective concentration, tissue exposure, or an in vivo dosing schedule.

BFH772 is not water soluble. It is reported to dissolve at concentrations of at least 53.4 mg/mL in DMSO and at least 15.33 mg/mL in ethanol. This makes it appropriate for workflows that permit a controlled organic vehicle, but unsuitable for protocols requiring a directly aqueous stock or a formulation with no organic solvent. It should also not be selected when broad-spectrum kinase inhibition is the experimental objective.

Protocol Parameters

• Assay: VEGFR2 biochemical kinase assay; Value: IC₅₀ 3 nM; Applicability: potency benchmarking and concentration-range design; Rationale: the value provides a product-level reference for VEGFR2 inhibition but should not be transferred directly to cellular or animal dosing; Basis: product dossier.
• Solvent: DMSO or ethanol; Value: solubility reported at or above 53.4 mg/mL in DMSO and 15.33 mg/mL in ethanol, with insolubility in water; Applicability: organic-solvent-compatible assays; Rationale: the vehicle determines whether a clear stock can be prepared and whether precipitation or solvent toxicity may confound results; Basis: product dossier.
• Identity: BFH772, CAS 890128-81-1; Value: molecular formula C₂₃H₁₆F₃N₃O₃, molecular weight 439.39 g/mol; Applicability: stock preparation, calculations, and lot verification; Rationale: identity and molecular weight should match the certificate of analysis before concentration calculations are finalized; Basis: product dossier.
• Storage: supplied solid; Value: store at -20°C; Applicability: routine compound storage; Rationale: stable solid handling is preferable to retaining a dilute solution because long-term storage of solutions is not recommended; Basis: product dossier.
• QC: analytical release; Value: purity above 96%; Applicability: research assays requiring a defined test article; Rationale: review the lot-specific certificate of analysis and safety data sheet before use, rather than assuming all lots have identical impurity profiles; Basis: product dossier.

Workflow Setup and QC Checklist

1. Define the biological question

Decide whether the experiment is measuring direct kinase inhibition, pathway output, endothelial behavior, or tumor-model response. Include an untreated control, a vehicle control, and a positive control appropriate to the assay. If the endpoint is downstream of VEGFR2, confirm that the model expresses the relevant receptor and responds to the intended ligand or stimulus. VEGF-related biology can vary substantially between cell types and culture conditions.

2. Prepare the test article

Inspect the vial label, lot number, appearance, and expiry or retest information. Weigh the solid using a calibrated balance and calculate the stock concentration from the stated molecular weight. Dissolve in DMSO or ethanol using a validated mixing procedure. Do not add water first to a concentrated stock, and do not assume that a clear solution remains stable after dilution into assay medium.

Prepare working dilutions shortly before use and keep the vehicle concentration consistent across all treatment wells. The acceptable vehicle percentage is a workflow parameter, not a product specification; determine it from the tolerance of the selected cells, enzyme system, or animal formulation. Examine diluted solutions for cloudiness, crystals, or adsorption to vessel walls before dosing.

3. Build the assay controls

For biochemical work, keep ATP, substrate, enzyme amount, incubation time, and detection conditions constant while varying BFH772 concentration. For cellular work, use matched vehicle controls and monitor viability or general morphology alongside the pathway endpoint. A loss of signal accompanied by nonspecific cytotoxicity should not be interpreted as selective VEGFR2 pathway inhibition without additional controls.

4. Confirm the run before interpretation

Accept a run only when vehicle wells, positive controls, background, and replicate variability meet pre-established laboratory criteria. Record the lot, stock solvent, preparation time, dilution sequence, plate map, and observed solution appearance. If a concentration-response curve is generated, fit it using a model selected in advance and report the assay conditions with the result.

The internal article BFH772 practical use and protocol guidelines complements this section with additional handling context, while this guide focuses on decision points for solvent compatibility and QC. The BFH772 technical use and workflow guide provides a related selectivity-focused perspective for assays using DMSO or ethanol.

Common Failure Modes and Fixes

Precipitation after dilution

A clear stock may become cloudy when transferred into aqueous medium. Check the dilution sequence, reduce the concentration step size, mix immediately, and inspect the final preparation before adding it to samples. If precipitation persists, the experiment should be redesigned around a validated solvent-compatible range rather than treating the nominal concentration as the delivered concentration.

Vehicle-driven signal changes

Unequal solvent levels can alter cell viability, membrane behavior, or assay detection. Prepare a common vehicle intermediate when practical, use matched vehicle in every condition, and include vehicle-only wells across the full plate. A vehicle control that is not biologically inert invalidates direct comparison with untreated wells.

Weak or inconsistent pathway inhibition

Do not assume that the biochemical IC₅₀ predicts the cellular response. Check receptor expression, ligand stimulation, compound exposure time, stock age, dilution accuracy, and endpoint timing. Confirm the result with an orthogonal readout, such as a proximal pathway marker plus a functional endpoint, when the project requires mechanistic confidence.

Loss of compound integrity during storage

Repeated handling of a solution can introduce concentration drift or degradation. Store the solid at -20°C, minimize unnecessary vial opening, and prepare only the amount of solution needed for the immediate experiment. Long-term storage of solutions is not recommended by the product dossier.

Scope and Limitations

BFH772 is an anti-angiogenic agent for research use, not a substitute for a validated clinical formulation or treatment protocol. The dossier reports oral administration suppressing tumor growth and angiogenesis in animal tumor models, but that information does not define a human dose, exposure target, formulation, or safety margin. The mention of clinical studies for rosacea likewise should not be interpreted as evidence that a laboratory assay has an established clinical translation pathway.

The reported selectivity profile supports focused VEGFR2 experiments, but selectivity is assay-dependent. The dossier describes approximately 500-fold reduced potency against related receptors listed in the product information and about 40-fold lower efficacy against B-RAF, RET, and TIE-2. These figures should be treated as product-dossier characteristics, not as a substitute for a custom kinase panel under the conditions used in a particular project.

Because BFH772 is water insoluble, it is a poor fit for aqueous-only workflows, uncontrolled media addition, or studies that require broad kinase coverage. It is also inappropriate to infer efficacy from nominal dose when precipitation, adsorption, solvent toxicity, or exposure loss has not been checked.

Conclusion

BFH772 provides a practical option for controlled VEGFR2 kinase and angiogenesis research when the assay can accommodate DMSO or ethanol. Start with the dossier-defined identity, potency, solubility, purity, and storage information; then validate stock preparation, vehicle tolerance, exposure, and assay-specific response in the intended model. Used with matched controls and explicit limitations, this VEGFR2 kinase inhibitor can support reproducible pathway studies without overstating what product-level potency or animal-model findings demonstrate.